The market has seen much downward price movement for drug-eluting stents across the vendor spectrum, providing new opportunities for savings that might otherwise go unnoticed. 

Join service line and value analysis expert Thomas Biel as he walks through the current coronary revascularization landscape. Thomas will highlight potential savings opportunities and share some best-practice tactics along the way.